Key Takeaways

• Treatment with ARNi results in a rise of many vasoactive peptides such as BNP, ANP etc.
• Being a target of neprilysin metabolism, BNP can be raised in patients on ARNi which is not reflective of an adverse prognosis
• NT-proBNP is not a substrate of neprilysin and hence its levels in Heart Failure patients treated with ARNi is reflective of a good prognosis and cardiac remodelling
• NT-proBNP is the preferred cardiac biomarker for monitoring treatment with ARNi